Compare BioNTech SE - ADR (BNTX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? BioNTech SE - ADR trades at $90.73 (market cap $22.86B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.95. Which is the better fit depends on your goals.
| BNTX | VCIT | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Fixed Income |
52-Week High | $119.34 | $84.82 |
52-Week Low | $83.89 | $81.45 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) trades at $81.45, down 0.44% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The fund maintains a competitive 0.03% expense ratio and approximately 5.17% SEC yield, positioning it as a cost-effective option for intermediate-duration corporate bond exposure. Recent dividend payments of $0.33-$0.34 per share demonstrate consistent income distribution to investors.
The outlook remains balanced with VCIT offering attractive yield characteristics amid moderate duration risk. Key considerations include interest rate sensitivity and corporate credit quality, with the fund providing diversification across 2,000+ investment-grade bonds. Market sentiment appears cautiously optimistic given the fund's low-cost structure and steady income profile in the current economic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
